A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

This study is checking a new medicine called danicamtiv for people who have a heart condition called dilated cardiomyopathy (DCM). DCM means your heart muscle has become stretched and weakened, making it harder for your heart to pump blood effectively around your body. This can lead to symptoms like breathlessness and tiredness. There are different reasons why people develop DCM, but this study is focusing on those whose DCM is either caused by a specific gene change (called 'genetic DCM') or runs in their family ('familial DCM'), even if the exact gene isn't found.

At the moment, there aren't any specific approved medicines designed just for genetic or familial DCM. This means doctors often use treatments that help with the general symptoms of heart failure. This study wants to see if danicamtiv can make a real difference in how well the heart pumps and how much physical activity people can manage. It also carefully checks if the medicine is safe and if people can take it without too many side effects.

To figure this out, some people in the study will take danicamtiv, and others will take a 'placebo', which looks exactly like the real medicine but doesn't contain any active drug. This helps the researchers truly understand if any improvements are due to danicamtiv itself, rather than other factors. They will use scans like echocardiograms (heart ultrasound) to measure heart function and will also look at exercise tests to see if people's ability to be active improves.